LON:NCYT Novacyt (NCYT) Share Price, News & Analysis GBX 51.60 -0.10 (-0.19%) (As of 12/20/2024 12:01 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider Trades About Novacyt Stock (LON:NCYT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novacyt alerts:Sign Up Key Stats Today's Range 50.58▼ 52.1650-Day Range 45.50▼ 59.5652-Week Range 42.95▼ 137Volume17,058 shsAverage Volume510,314 shsMarket Capitalization£36.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNovacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental. The Company is divided into three business segments: Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments Research Use Only Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV"). For more information, please refer to the website: www.novacyt.comRead More… Receive NCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter. Email Address NCYT Stock News HeadlinesNovacyt’s Liquidity Update and Market PresenceDecember 2, 2024 | tipranks.comNovacyt S.A. (NVYTF) Q2 2024 Earnings Call TranscriptSeptember 28, 2024 | seekingalpha.comThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…December 21, 2024 | Crypto 101 Media (Ad)Novacyt Share Chat (NCYT)September 16, 2024 | lse.co.ukCiti Fun 26 Share ChatAugust 28, 2024 | lse.co.ukMike Lynch's family devastated and in shock, says spokespersonAugust 25, 2024 | lse.co.ukTOP NEWS: UK retail sales rise in July amid triple sports boostAugust 16, 2024 | lse.co.ukLONDON MARKET EARLY CALL: Stocks called up after New York boostAugust 16, 2024 | lse.co.ukSee More Headlines NCYT Stock Analysis - Frequently Asked Questions How have NCYT shares performed this year? Novacyt's stock was trading at GBX 61.50 at the start of the year. Since then, NCYT shares have decreased by 16.1% and is now trading at GBX 51.60. View the best growth stocks for 2024 here. How do I buy shares of Novacyt? Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Novacyt own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novacyt investors own include BP (BP), Mesa Air Group (MESA), Global X Cloud Computing ETF (CLOU), genedrive (GDR), Invesco High Yield Equity Dividend Achievers ETF (PEY), Walmart (WMT) and boohoo group (BOO). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolLON:NCYT CUSIPN/A CIKN/A Webwww.novacyt.com Phone33 1 39 46 51 04FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-37,360,000.00 Net Margins-202.80% Pretax MarginN/A Return on Equity-42.04% Return on Assets-27.98% Debt Debt-to-Equity Ratio18.67 Current Ratio4.04 Quick Ratio4.46 Sales & Book Value Annual Sales£18.56 million Price / Sales1.96 Cash FlowGBX 88.90 per share Price / Cash Flow0.58 Book ValueGBX 100 per share Price / Book0.52Miscellaneous Outstanding Shares70,630,000Free FloatN/AMarket Cap£36.45 million OptionableNot Optionable Beta-1.86 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (LON:NCYT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novacyt S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novacyt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.